3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
81
Leukemia
41
Gastrointestinal Stromal Tumors
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Leukemia, Myeloid, Chronic-Phase
27
Blast Crisis
13
Neoplasms
10
Neoplasm Metastasis
10
Melanoma
10
Brain Neoplasms
10
Lung Neoplasms
9
Prostatic Neoplasms
8
Leukemia, Myeloid, Acute
8
Gliosarcoma
8
Glioblastoma
8
Leukemia, Myeloid, Accelerated Phase
7
Glioma
6
Carcinoma, Non-Small-Cell Lung
6
Sarcoma
5
Philadelphia Chromosome
5
Oligodendroglioma
5
Recurrence
4
Primary Myelofibrosis
4
Polycythemia Vera
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Central Nervous System Neoplasms
4
Breast Neoplasms
4
Astrocytoma
4
Interventions
talimogene laherparepvec
1
peginterferon alfa-2b
1
nilotinib
1
mirdametinib
1
binimetinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vincristine
1
Temozolomide
1
Talaporfin
1
Sirolimus
1
Restraint, Physical
1
Ranibizumab
1
Radiosurgery
1
Photochemotherapy
1
Neurofibromin 1
1
Imatinib Mesylate
1
Everolimus
1
Elasticity Imaging Techniques
1
Deoxycholic Acid
1
Cryotherapy
1
Celecoxib
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neurofibroma
×
Imatinib Mesylate
×
Clear all
NCT01140360
2017-07-02
0908-09
Indiana University
Phase 1/2
Completed
21 enrolled
8 charts